氨甲环酸在全膝关节置换术中的疗效:一项网络Meta分析
该网络Meta分析检索截至2017年7月的文献,从2113篇中纳入67篇,评估氨甲环酸(TXA)在初次全膝关节置换术(TKA)中减少失血和输血风险的疗效。局部、静脉和口服TXA均优于安慰剂,但无某种剂型明显更优;重复给药和高剂量未显著进一步减少失血或输血风险。切皮前静脉给药证据不一致。
要点
- 局部、静脉和口服TXA均优于安慰剂减少失血和输血风险,但无剂型明显更优。
- 重复静脉或口服给药及较高剂量静脉或局部TXA未显著减少失血或输血风险。
- 切皮前静脉TXA降低输血风险但失血量无影响,证据不一致;中等证据支持切皮前给药提高疗效。
核心结论
- 强证据支持TXA可减少初次TKA后失血和输血风险。
- 无某种TXA剂型、剂量或给药次数明显改善血液保护特性。
- 中等证据支持切皮前静脉给予TXA以提高疗效。
研究设计与样本
- 网络Meta分析,检索Ovid MEDLINE、Embase、Cochrane Reviews、Scopus和Web of Science数据库截至2017年7月的文献。
- 从2113篇文献中经严格评价纳入67篇代表最佳可用证据的研究。
- 纳入研究均进行定性和定量同质性检验,直接和间接比较以网络Meta分析进行,并检验一致性。
主要发现
- 局部、静脉和口服TXA剂型在减少失血和输血风险方面均优于安慰剂,但无剂型明显更优。
- 重复静脉和口服TXA给药及较高剂量静脉和局部TXA未显著减少失血或输血风险。
- 切皮前静脉TXA给药结果不一致:降低输血风险但对失血量无影响。
关键数值与推荐
- 强证据支持TXA减少初次TKA后失血和输血风险的疗效。
- 中等证据支持切皮前静脉给予TXA以提高疗效。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A growing body of published research on tranexamic acid (TXA) suggests that it is effective in reducing blood loss and the risk for transfusion in total knee arthroplasty (TKA). The purpose of this network meta-analysis was to evaluate TXA in primary TKA as the basis for the efficacy recommendations of the combined clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Academy of Orthopaedic Surgeons, Hip Society, Knee Society, and American Society of Regional Anesthesia and Pain Medicine on the use of TXA in primary total joint arthroplasty. METHODS: We searched Ovid MEDLINE, Embase, Cochrane Reviews, Scopus, and Web of Science databases for publications before July 2017 on TXA in primary total joint arthroplasty. All included studies underwent qualitative and quantitative homogeneity testing. Direct and indirect comparisons were performed as a network meta-analysis, and results were tested for consistency. RESULTS: After critical appraisal of the available 2113 publications, 67 articles were identified as representing the best available evidence. Topical, intravenous (IV), and oral TXA formulations were all superior to placebo in terms of decreasing blood loss and risk of transfusion, while no formulation was clearly superior. Use of repeat IV and oral TXA dosing and higher doses of IV and topical TXA did not significantly reduce blood loss or risk of transfusion. Preincision administration of IV TXA had inconsistent findings with a reduced risk of transfusion but no effect on volume of blood loss. CONCLUSIONS: Strong evidence supports the efficacy of TXA to decrease blood loss and the risk of transfusion after primary TKA. No TXA formulation, dosage, or number of doses provided clearly improved blood-sparing properties for TKA. Moderate evidence supports preincision administration of IV TXA to improve efficacy.
引用
- Fillingham YA, Ramkumar DB, Jevsevar DS, et al. The Efficacy of Tranexamic Acid in Total Knee Arthroplasty: A Network Meta-Analysis. J Arthroplasty. 2018. PMID: 29805106. doi:10.1016/j.arth.2018.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。